Tiziana Life Sciences

Today Gabriele Cerrone, Chairman and CEO of Tiziana Life Sciences announced that we have received $3.2m of Non Dilutive funding and provided an exciting update on the progress of the company. Thank you Proactive for the interview $TLSA https://lnkd.in/esNVQmZd

Today we have announced that we are to dose the first patient with moderate Alzheimer's disease with intranasal foralumab under a new expanded access program allowed by the FDA. We also look forward to commencing our phase 2 trial in early symptomatic AD. #Alzheimers #AD #Microglia https://lnkd.in/eYvedWWi

We have created an animation of the MoA of Intranasal Foralumab and it's effect on microglia in the brain of a patient with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The PET scan shown in the animation is from an actual patient in our expanded access program after 6 months of treatment. #MultipleSclerosis #MS #SPMS #PIRA $TLSA https://lnkd.in/eFDRqZiB

Today we have announced that the FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis. $TLSA #MultipleSclerosis #MS #SPMS #Foralumab #FDA https://lnkd.in/e7NcdTry

🚀 Exciting News! Launching Our New Website! 🚀 We are thrilled to announce the launch of the new Tiziana Life Sciences website! 🌐✨ Discover the future of medical innovation with cutting-edge medical animation that bring our groundbreaking research and developments to life. Our enhanced website is designed to provide a more engaging and informative experience for healthcare professionals, researchers, and patients alike. 🔗 Visit us now at https://lnkd.in/eFDRqZiB $TLSA #MultipleSclerosis #Alzheimers #ALS #Foralumab #SPMS #MS

Today we announced 80% of patients in our na-SPMS program saw a qualitative improvement in neuroimaging at 6 months of treatment with intranasal foralumab. $TLSA #MultipleSclerosis #SPMS #MS #PET Tarun Singhal, MBBS, MD https://lnkd.in/gi8x5A3e

Today we announced that we have submitted a grant application to The ALS Association to fund a groundbreaking clinical trial in ALS with intranasal foralumab. $TLSA #ALS #Foralumab #ClinicalTrial #Phase2 #Intranasal https://lnkd.in/eZKKRdhK

Today we announced Howard Weiner M.D, Chairman of our scientific board will today receive a prestigious award as a "Giant of MS" for his research work in Multiple Sclerosis. Congratulations and thank you for all of your ground breaking research with intranasal foralumab in MS. CMSC NeurologyLive $TLSA #multiplesclerosis #SPMS #MS https://lnkd.in/geJVa8tH

Today we announced that we have submitted a request to the FDA for Orphan drug designation for intranasal foralumab for non-active secondary progressive multiple sclerosis. This would make foralumab the first therapy for na-SPMS to receive orphan drug designation. $TLSA #multiplesclerosis #PIRA #SPMS #MS https://lnkd.in/gNV7CTdZ

Fantastic interview with Tarun Singhal, MBBS, MD discussing findings in our nasal Foralumab expanded access program treating patients with multiple sclerosis. 70% of patients seen improvement in Fatigue. #MS #lifesciences #multiplesclerosis #monoclonalantibodies #PIRA #microglia